1. Medicon
Village
For people´s health and
well-being
Ursula Hultkvist Bengtsson
Executive Vice President

2. Medicon Village – Medicon Valley
The Village in the Valley
Medeon
Ideon
Medicon
Village

3. Titel, namn och tidpunkt

4. 2 March 2010
– AstraZeneca will move to Mölndal – staff meeting –
900 people to lose their jobs
2 March 2010
– Allan Larsson appointed chief negotiator and to
develop a Life Science concept by FIRS
(Forsknings- och Innovationsrådet i Skåne =
Research and Innovation Council Skåne)
14 January 2011
– Mats Paulsson´s Foundation announced. 100 milj
SEK donated and surplus reinvested into research
and innovation.
10 January 2012
– Medicon Village being launched
From bad to good…

5. AstraZeneca exit from Lund
Achievements and learnings
Governance: Accountability for
managing the change and external
stakeholders (regional partners, media
etc.) very unclear the first 5 months.
Great improvement during autumn 2010
when leadership team was empowered
and resources made available.
Success factors
•Transformation from global to local
•External, pro-active communication plan
•Local accountabilities with senior team
members; well defined objectives;
budget/resource; focus on solutions and
transparency
•Internal AZ project teams working closely with
LCT on well defined projects
•LCT culture and behaviours: Silos broken, one
for all – all for one; breathe the air in Lund!
Engagement: Critical for keeping up
the spirit and finding the strength and
commitment to deliver the objectives in a
difficult situation.
Success factors
•Dedicated local leaders
•A variety of events and activities were arranged
both by LCT and functions
• Career support activities
• Focus on motivation and well-being
•Site sale – an extremely important
achievement!
• Handover project (Buildings/instruments,
IS/IT, competence)
5Lund LCT | October 2011
Never underestimate
peoplesʼ driving
force to do a good
job. But donʼt take it
for granted!

6. Never underestimate
peoplesʼ driving
force to do a good
job. But donʼt take
it for granted!
AstraZeneca exit from Lund
Achievements and learnings
Recruitment and relocation:
Functional reorganisations in parallel with
moving a business with people, projects and
equipment is more complicated than one can
ever imagine
•New organisation in Mölndal not in place to
provide pull until late 2010/early 2011
•More people may have moved with
firmer/faster process
Redundancy: Redundancy/early retirement
packages; people had to wait too long for
information, but perceived as generous when it
came
•Local HR Center an excellent improvement
when in place, but would have been even better
if also early retirement was managed locally
•Local career support activities outstanding!
Communications: After announcement
of the site closure and during a large part of
2010 the general perception was that there was
no communication by global R&D.
Initially the unions “provided the lifeline” and
local functional leadership provided the stability.
From Q3 2010 and forward a strong
improvement was seen in communication when
local ownership and resources came in place.
Success factors
•Visible local leadership (by LCT and functions)
provided clarity and a sense of security
•Several well-managed communication
channels
6Lund LCT | October 2011 R&D | PMO

7. Executive summary
• 85% had moved in August 2011
80% of staff signed up have their work‐place in
Mölndal by end of August 2011 and all
relocated by end of October 2011
• 85% had a plan
75% of people made redundant have a plan for
new opportunities within 6 months
• ready to hand over before December
2011. Steering group decided on
January 2012.
Lund site transferred to new owners at the
latest by end of December 2011
• Survey among employees > 90 % agreed
or strongly agreed
Exiting Lund perceived to be done in a
responsible way with respect for employees
• Outstanding (Swedish independent
analysis by Mediapilot AB)
Maintain corporate reputation
Lund LCT achievements and deliverables
7Lund LCT | October 2011
Objectives Results

8. Swedish Independent media analysis by Mediapilot AB
• ”The conclusion is that AstraZeneca in many ways have
succeeded in turning negative news to positive publicity by
showing responsibility and understanding of their employees.
Even though the news around the site closure are negative
per se, there has been a lot of positive outcomes.”
1 March 2010 – 30 September 2011
8Lund LCT | October 2011 R&D | PMO

9. What has happened with the employees Nov 2011?
892 employees in Lund March 2, 2010
9
Moved to Mölndal (23%)
(40% of 520 that were asked)
Retired (12,1%)
External – New Company (32,3%)
Business start up (7,7%)
Education(8,2%)
Active job hunters or
decided to take a break
(16,5%)
More than 80% know their future!

10. Medicon
Village
For people´s health and
well-being

11. Malmö
Copenhagen/
Kastrup
Lund
Öresundsbridge
Ideon
University
Cooperation ahead!
ESS
MAX IV
Medicon
Village
SUS

12. Medicon Village
Research, innovation and business
ESS Head Office
Conference and restaurant
Appr. 30 life science companies
(B2B)
Lund Life Science Incubator
appr. 20 companies
Cancer Centre Region Skåne
Biobank
Innovation partners and institutes
Primary Care Skåne
Science Support & labshop

13. Facts & Figures
March 2013
• Launched 10th January 2012
• Former AstraZeneca site
• Laboratories 30 000 m2
• Offices, Conference 50 000 m2
• >600 members
• An additional 200 cancer researchers from June 2013
• >75 organizations
– 22 product companies
– 51 service companies/providers
– 2 institutes
13

14. Life Science
Foresight Institute
Regionalt biobankscentrum

15. Medicon Village members
(product and R&D companies)
Cancer Resp./inflam. Other indications Prevent
ion
Material
Diagnostics Treatment Diagnostics Treatment Prevention Diagnostics Care Treatment Other
Chemistry
Medtech
E‐
Health/m‐
health
Nano‐
medicine
Biotech
Pharma
2013 03 10

16. Entire value chain –
embracing the whole individual
At Medicon Village we want to create an environment
where research, innovation and entrepreneurship work
together to create value for people’s health and
wellbeing

17. What makes Medicon Village unique?
• A development company owned by
Mats Paulsson´s Foundation for
research, innovation and societal
development
• Profits reinvested in research and
innovation
• Members moving into premises
ready to use - complete R&D site
• The entire value chain, from
researchers to innovators and
businessmen are represented
• Giving small companies the same
advantages that can normally only
be enjoyed by large companies
TRIPLE HELIX in action
BOARD MEMBERS OF MATS PAULSSON´S FOUNDATION:
Allan Larsson, former chairman of Lund University
Pia Kinhult, First Governor ,Chair of the Regional Executive Committee
Göran Grosskopf, Mats Paulsson´s Foundation
Mats Paulsson, Mats Paulsson´s Foundation
Per Eriksson, Vice-Chancellor, Lund University

18. Prevention Diagnosis Treatment Care
From basic research to
mature companies
covering the entire value
chain
Body and Mind inseparable

19. Lund University & Medicon Village
Creating one of strongest cancer
research units in Europe

20. Mobile
Health
Processing
Knowledge
1+1=5
Processing start-
up incubation
Nanomedicin
center
One stop shop:
Max IV
ESS
Science Village
Scandinavia
Externalization
&
Partnerships
Drug Delivery
Institute
Move the challenge at Medicon Village
Health
Informatics
Medicon
Village
Clinics
Medicon
Village
Foundation
Medicon
Skills
Centre

21. Today

22. Possible expansion

23. A world class player within Life
Science
Externalization is an
important part of Medicon
Village’s concept and
international partnerships
are being worked on,
both in the east and over
the Atlantics to the west.

24. World class cluster criteria
Jones Lang LaSalle (2011)
Situation in Medicon Valley?
• Educated workforce
• Venture and investment capital
• Centers of excellence and innovation
• Industry-friendly political structures
• Institutions of higher learning
• Target oriented economic development incentives
• Patent protection
• Supporting infrastructure

25. Medicon Village
Twin Clusters &
Partnerships
• Twinning 2013, 2014, 2015
• Partnerships near by
• Proposals

26. Twinning Life Science clusters
- between similar eco systems

27. Memorandum of Understanding: Wales
The participants will strongly pursue for mutual benefit the potential for collaboration in the field of Life Sciences,
technology, innovation, research and development and their commercial exploitation.
The participants will promote the establishment of co-operative relationships between companies, organisations,
universities and investors in their respective countries.
The participants will promote business and trade opportunities and provide practical assistance to organisations,
universities and other innovative enterprises wishing to collaborate or locate in the other region.
The participants will promote international business development, encouraging innovation and research collaborations
and facilitating the identification of partners, collaborators and investors between the regions.
The participants will invite the other region to participate in relevant conferences in the field of Life Sciences.
The participants will seek to maintain regular contact to facilitate consultations on the exchanges and cooperation as
well as matters of common concern.
The participants will also seek to involve other parties in the implementation of this memorandum.

28. Memorandum of Understanding:
Wales Life Science Cluster and Medicon Village
Launch 19 March 2013
Growth
via
Twinning
Growth
via
Twinning
ConnectingConnecting
PromotingPromoting
SupportingSupporting
PartneringPartnering
EnjoyingEnjoying
ExcellingExcelling
Co‐operatingCo‐operating
CollaboratingCollaborating
ConsultingConsulting
DevelopingDeveloping
EncouragingEncouraging
FacilitatingFacilitating
ParticipatingParticipating
ImplementingImplementing
InvolvingInvolving
ExchangingExchanging
AssistingAssisting

29. Twin Clusters (1) –
between similar eco systems
• Areas of interest:
• Innovation - Process and Product
• Cancer
• Diabetes
• Neuroscience
• Translational research
• Philanthropy and Venture Capital
• Cooperation/invest perspective:
• Promote the establishment of co-operative relationships between companies
and organizations in our respective countries.
• Promote international business development, encouraging innovation and research collaborations
between the two regions.
• Facilitate the identification of partners, collaborators and (international) investors to provide
international business development.
• Explore opportunities in respective innovation systems

30. Twin Clusters (2)
• Company perspective:
• Co-incubation of start-ups
• Port of entry to respective country for growth of a company
• Promote business opportunities and access to trade opportunities in respective countries.
• Research perspective:
• Facilitate research collaboration regarding e.g. ESS and respective university – bridging between
teams and individuals
• Bio banks
• Stimulate collaboration cross-institutions
– Including hospitals and healthcare
– Identifying partners

31. Thank you
and
Welcome
back to
Medicon Village
Ursula.HultkvistBengtsson@mediconvillage.se
+46 709 131236

32. Lund Life Science Incubator is a business incubator which helps
entrepreneurs and small companies within the field of Life Science to
develop and commercialize their ideas
Lund Life Science Incubator
Structural Biology and
Structure-Based Drug
Design Outsourcing
A research and development
company dedicated to find new
ways to promote better health for
patients with autoimmune
disorders
Provides life science and
drug development
consultancy with an
emphasis on biology and
translational science.
Developes BioBarrier™,
an effective and user
friendly post-surgical
adhesion barrier spray.
The incubator hosts both product companies and service companies,
working in different fields and in different stages of development. This
breadth provides an dynamic environment and knowledge exchange.

33. The European Spallation Source
The European Spallation Source (ESS) is a multi-disciplinary research
centre based on the world’s most powerful neutron source. It is a
European project with, at present, 17 Partner Countries, with Sweden and
Denmark as host nations.
The facility will be around 30 times brighter than today's leading facilities,
enabling new opportunities for researchers in the fields of life sciences,
energy, environmental technology, cultural heritage and fundamental
physics.
The European Spallation
Source is one of the largest
science and technology
infrastructure projects
being built today.